Previous 10 | Next 10 |
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2022 Results Conference Call November 3, 2022 08:30 AM ET Company Participants Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Matt Roache - Director ...
Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q3 Non-GAAP EPS of $0.28 beats by $0.01 . Revenue of $108.64M (+4.7% Y/Y) misses by $1.76M . Reaffirms FY22 Guidance: In 2022, Ironwood continues to expect: U.S. LINZESS Net Sales Growth...
– LINZESS ® (Iinaclotide) EUTRx prescription demand growth in Q3 2022 increased 10% year-over-year – – Ironwood and its partner, AbbVie, plan to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FD...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 3, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (...
Summary Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages. Other healthcare industries don’t look attractive. Focus on a biotech ETF: GNOM (and why I don’t like it). ...
Summary Today, we are revisiting Ironwood Pharmaceuticals for the first time since April of 2021. The company continues to live off its Lizness franchise and is putting its cash flow to good use in paying down debt and buying back stock. Given that Ironwood Pharmaceuticals sto...
AbbVie ( NYSE: ABBV ) and Ironwood Pharmaceuticals' medicine ( NASDAQ: IRWD ) Linzess met the main and secondary goals of a phase 3 trial in pediatric patients aged six years to 17 years with functional constipation (FC). Linzess (linaclotide) is approv...
– Study met primary and secondary endpoints – – Results add to body of data supporting the safety of linaclotide for this patient population – – There are currently no FDA approved prescription pediatric therapies for Functional Const...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Thursday, September 8, 2022 at 8:00 a.m. ET at the Encore Boston Harbor in Everett, MA. A live webcast of Ironwood’s fireside chat will be ac...
Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...